Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.

By G. Bucaneve, A. Micozzi, F. Menichetti, P. Martino, M. Dionisi, G. Martinelli, B. Allione, D. D’Antonio, M. Buelli, A. Nosari and 10 more. New England Journal of Medicine, 2005

614 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/463daf5a61c3a18fc2fb5b64b59216f14c2bdb6e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. João B. Xavier
2. Nicholas D. Socci
3. P. Keeling

In Immunology

1. M. V. D. van den Brink
2. Eric G. Pamer

In Oncology

1. Eric G. Pamer

Citations in the corpus

• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “Antibacterial prophylaxis with a fluoroquinolone (ie, levofloxacin) to prevent bacterial infections should be strongly considered for adult HCT patients with anticipated neutropenic periods of 7 days or more (BI) [146-150] (Appendix 1).”
• Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. (2012, result): “This finding supports prior studies of fluoroquinolone prophylaxis in neutropenic patients [38, 39] and provides insight into the mechanism of protection.”